Latest filing published 07 Mar 2025 for Vaxcyte, Inc., €101k.
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
This profile gathers the share dealings of Mikhail Eydelman in Vaxcyte, Inc., where the filings describe the role as senior executive. We count 91 filings; the first trade dates from 7 June 2022 and the latest from 5 March 2025.
Sales make up the whole of the open-market record (59 sales, €5.7M). Besides market trades, the filings include 13 share grants and 18 option exercises. So far in 2025, the count stands at no purchases and 11 sales.
The record was last updated on 7 March 2025 with an open-market sale (€7,627) in Vaxcyte, Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
24 of 24 declarations